5th NovAliX Conference - Biophysics in Drug Discovery 2018
June 13 - 15, 2018 - Boston MA USLD Organisation
bernard@ldorganisation.com
Phone:+32 486269574
The use of biophysical methods has become pervasive in the drug discovery process, allowing not only to identify low-affinity hits at the screening stage but also to obtain detailed information on target / ligand interactions at more advanced stages (see the review Renaud et al. 2016 Nat. Rev. Drug Discov. 15: 679-698). This is perfectly illustrated by the success of FBDD (fragment-based drug design), where the progress of biophysical techniques in terms of sensitivity, speed, and automation has been instrumental (see the review Erlanson et al. 2016 Nat. Rev. Drug Discov. 15: 605-619). Indeed FBDD is now widely adopted in both academia and the pharmaceutical industry and has lead to 2 approved drugs and more than 30 compounds being evaluated in clinical trials. The fifth edition of the conference intends again to bring together biophysicists and medicinal chemists to improve the synergy between their disciplines in order to deliver better drugs on a shorter timeline. This year, the Scientific Programme will include the following sessions : - Membrane Proteins - Protein-Protein Interactions - Cryo-EM (Special Focus of the Conference) - Biotherapeutics - Target Engagement - Hot Topics And we are extremely honored that Professor Martin Karplus has agreed to give the Keynote Lecture. The Scientific Programme will be completed by short Exhibitor Presentations, a Poster Session and a Commercial Exhibition.